As Molbio Diagnostics conducts its IPO from August 10 to August 12, 2026, the company faces scrutiny over a ₹882 crore government tender for TB diagnostic kits. Investors are focusing on this issue due to the company's high dependence on government contracts for revenue. While the government has defended the tender, the debate highlights the risks involved in relying on public procurement policies.
Molbio Diagnostics, which is currently holding its Initial Public Offering (IPO) between August 10 and August 12, 2026, has entered the spotlight due to a controversy surrounding a ₹882 crore government tender for tuberculosis diagnostic kits. The tender, issued by the Central Medical Services Society (CMSS), specifies the procurement of 1.5 crore TrueNat MTB chips, a proprietary technology manufactured by the company.
Understanding the Tender Controversy
The core of the debate lies in the tender’s requirement for a specific brand. Experts and market observers have questioned why the tender explicitly mentions 'TrueNat' chips, especially in light of a February 2026 assessment by the Indian Council of Medical Research (ICMR). That assessment evaluated four molecular diagnostic tests—QuantiPlus, PathoDetect, TrueNat, and GeneXpert—and concluded that all four met international technical standards. The report also highlighted significant price differences, noting that QuantiPlus was the most economical option among those tested.
The government, through the Ministry of Health and Family Welfare, has officially defended the tender structure. Officials stated that the procurement is designed to utilize an existing national infrastructure of over 9,000 TrueNat machines already installed across India. Furthermore, the ministry clarified that the decision to prioritize TrueNat chips was driven by the platform's specific ability to diagnose multidrug-resistant tuberculosis, a requirement they indicated was not met by the lower-cost alternatives assessed.
Financial Context for Investors
For potential investors, this controversy underscores a specific business risk: revenue concentration. A significant portion of Molbio Diagnostics’ revenue—exceeding 80%—is derived from a limited number of government and international aid agency clients. When a company relies heavily on a small group of public-sector customers, any changes in government procurement rules, tender specifications, or public policy can directly impact its financial performance.
While the company operates in a growing sector, it faces competition from emerging, lower-cost diagnostic technologies. The current debate illustrates how sensitive the company’s business model is to the evolving requirements of public health programs and the competitive landscape of molecular diagnostics.
The company is seeking to raise approximately ₹939.70 crore through this IPO, consisting of a fresh issue of ₹200 crore and an offer for sale of ₹739.70 crore. The shares are scheduled for listing on the NSE and BSE on August 17, 2026. As the IPO process concludes, the key monitorables for investors will include the company's ability to diversify its client base, manage competition from newer technologies, and navigate future government tendering policies. Market participants will likely track whether these regulatory and procurement discussions influence the long-term demand for the company's flagship TrueNat products.